Anti­BCMA CAR­T cell immunotherapy for relapsed or refractory multiple myeloma.

AntiBCMA CART cell immunotherapy for relapsed or refractory multiple myeloma.

Zhang, Xiaohui; Ouyang, Chenxi; Sun, Guofeng; Liu, Hongfeng; Qi, Junyuan; Suo, Xiaohui.

Afiliação

Zhang X; Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R. China.
Ouyang C; Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Beijing 100037, P.R. China.
Sun G; Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R. China.
Liu H; Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R. China.
Qi J; Good Clinic Practice, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, P.R. China.
Suo X; Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R. China.

Exp Ther Med ; 26(4): 471, 2023 Oct.

Article em En | MEDLINE | ID: mdl-37664681